The Company also provided an update on NCX 470 Development. Poster Title: Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC Trial A ...

More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost New analysis provides additional data demonstrating differentiation of NCX ...